The ROS1ders Issues RFA for $75K ROS1+ Cancer Research Grant
The Californer/10231160

SACRAMENTO, Calif. - Californer -- The ROS1ders is pleased to issue their inaugural Request for Application (RFA) to study ROS1-positive (ROS1+) cancer.

"ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer and other types of cancer," said Janet Freeman-Daily, MS, co-founder and president of The ROS1ders. "While oral targeted therapies are approved to treat it, the drugs don't work for everyone, and they eventually stop working. We need more research to improve quality of life and survival for all patients with this disease."

The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward research projects focused on ROS1+ cancer. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research and is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.

More on The Californer

• Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
• AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
• First Partner highlights apprenticeship program helping underrepresented youth break into careers in California's iconic entertainment industry
• Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
• Cal State LA secures funding for two artificial intelligence projects from CSU

"Seed grants, as the name suggests, allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the real seeds of breakthroughs."

The award program uses a two-step application process. An applicant must first submit a letter of intent (LOI) due March 31, 2023. A subset of those applicants will be invited to submit a full application due June 15, 2023. Award recipients will be announced in late summer. For more information, visit https://theros1ders.org/seed-grant-program.

More on The Californer

• Colbert Packaging Announces WBENC Recognition
• New Mobile Car Detailing Platform Connects Drivers with On-Demand Local Pros
• Over the past three months, California seized $476 million worth of unlicensed cannabis products
• California scores more clean energy records: 9 in 10 days this year partially powered by 100% clean energy
• "Mobile Suit Gundam" Takes Over San Diego Comic-Con 2025

About the ROS1ders

The ROS1ders, Inc. is a non-profit public benefit corporation that brings together a global group of patients and their family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Founded in 2015 by ROS1+ lung cancer patients, it is the largest collection of ROS1+ patients and caregivers in the world, with hundreds of members from dozens of countries. The organization is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Please visit theros1ders.org to learn more.